Viragen Reports Peptide Agreement Expired

Viragen announced that it has elected not to exercise an exclusive option to license VG104, the IEP 11 peptide, from the University of Miami. The IEP 11 peptide was being researched as a potential cancer therapeutic. In light of Viragen's decision, the option has expired and all development activities relating to VG104 have been discontinued.
PharmaLive